Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Jun-30-23 | Jun-30-22 | Jun-30-21 | Jun-30-20 | Jun-30-19 | Jun-30-18 |
| | 10-K | 10-K | 10-K | 10-K | S-1 | S-1/A |
| Revenues: |
| BayMedica | 4.1 | 1.1 | | | | |
| Other | 1.4 | | | | | |
| Revenues | 5.5 | 1.1 | 1.9 | 0.0 | 0.0 | 0.0 |
| Revenue growth [+] | 405.0% | -42.8% | | | | |
| BayMedica | 279.6% | | | | | |
| Cost of goods sold | 2.4 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 3.1 | 0.5 | 1.9 | 0.0 | 0.0 | 0.0 |
| Gross margin | 55.9% | 49.9% | 100.0% | | | |
| Selling, general and administrative [+] | 6.2 | 7.2 | 4.5 | 3.2 | 4,296.5 | 6.1 |
| General and administrative | 6.2 | 7.2 | 4.5 | 3.2 | 4,296.5 | 6.1 |
| Research and development | 3.7 | 7.3 | 5.3 | 5.8 | | |
| Other operating expenses | 0.7 | 1.1 | 1.7 | -0.2 | 4,798.7 | 1.9 |
| EBITDA [+] | -7.6 | -15.0 | -9.6 | -8.9 | -9,095.2 | -7.9 |
| EBITDA growth | -49.5% | 56.0% | 8.7% | -99.9% | 114738.5% | |
| EBITDA margin | -138.0% | -1380.3% | -506.4% | | | |
| Depreciation | 0.2 | 0.2 | 0.0 | 0.0 | 119.4 | 0.1 |
| EBITA | -7.8 | -15.2 | -9.7 | -8.9 | -9,214.6 | -8.0 |
| EBITA margin | -141.7% | -1397.4% | -507.5% | | | |
| Amortization of intangibles | | | 0.1 | 0.1 | | |
| EBIT [+] | -7.8 | -15.2 | -9.8 | -9.0 | -9,214.6 | -8.0 |
| EBIT growth | -48.8% | 55.9% | 8.6% | -99.9% | 114538.1% | |
| EBIT margin | -141.7% | -1397.4% | -512.8% | | | |
| Non-recurring items [+] | 0.6 | 3.5 | | | | |
| Asset impairment | | 3.5 | | | | |
| Interest income | 0.5 | 0.1 | 0.0 | 0.1 | | |
| Interest income | 0.5 | 0.1 | 0.0 | 0.1 | | |
| Other income (expense), net [+] | | | -0.5 | -0.1 | -33.9 | |
| Unrealized gain/loss on derivatives | | | 0.2 | | | |
| Gain (loss) on foreign currency transactions | | | -0.2 | 0.1 | 33.9 | |
| Pre-tax income | -7.9 | -18.6 | -10.2 | -8.9 | -9,248.5 | -8.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -7.9 | -18.6 | -10.2 | -8.9 | -9,248.5 | -8.0 |
| Net margin | -144.5% | -1707.3% | -535.9% | | | |
| |
| Basic EPS [+] | ($3.25) | ($33.17) | ($37.96) | ($1.71) | ($1,781.27) | ($1.86) |
| Growth | -90.2% | -12.6% | 2116.9% | -99.9% | 95561.1% | |
| Diluted EPS [+] | ($3.25) | ($33.17) | ($37.96) | ($1.71) | ($1,781.27) | ($1.86) |
| Growth | -90.2% | -12.6% | 2116.9% | -99.9% | 95561.1% | |
| |
| Shares outstanding (basic) [+] | 2.4 | 0.6 | 0.3 | 5.2 | 5.2 | 4.3 |
| Growth | 336.6% | 108.6% | -94.9% | 0.6% | 20.3% | |
| Shares outstanding (diluted) [+] | 2.4 | 0.6 | 0.3 | 5.2 | 5.2 | 4.3 |
| Growth | 336.6% | 108.6% | -94.9% | 0.6% | 20.3% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|